Catalog No.: PC-25027Not For Human Use, Lab Use Only.
JN-170 is a highly selective, first-in-class, orally bioavailable inhibitor of SLC6A19 (B0AT1) with IC50 of 97 nM against mouse SLC6A19 in the isoleucine transport assay, > 10-fold less potent against human SLC6A19 (IC50=1.25 μM).
JN-170 is a highly selective, first-in-class, orally bioavailable inhibitor of SLC6A19 (B0AT1) with IC50 of 97 nM against mouse SLC6A19 in the isoleucine transport assay, > 10-fold less potent against human SLC6A19 (IC50=1.25 μM).
JN-170 (50 -250 mg/kg, oral) caused a dose-dependent increase in urinary amino acid excretion in WT C57Bl/6J mice.
JN-170 significantly drove reductions in plasma Phe in an exposure-related manner.
